Eventide Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Eventide Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-30,900	Closed	-$14.9M	–	174
2020 Q4	$14.9M	Hold	30,900	–	–	0.23%	99
2020 Q3	$17.3M	Hold	30,900	–	–	0.34%	83
2020 Q2	$19.3M	Hold	30,900	–	–	0.42%	71
2020 Q1	$15.1M	Buy	+30,900	New	+$12.7M	0.49%	65
2018 Q4	–	Sell	-23,000	Closed	-$9.29M	–	147
2018 Q3	$9.29M	Hold	23,000	–	–	0.34%	79
2018 Q2	$7.93M	Hold	23,000	–	–	0.33%	79
2018 Q1	$7.92M	Buy	23,000 +15,500	+207%	+$5.39M	0.37%	74
2017 Q4	$2.82M	Hold	7,500	–	–	0.15%	98
2017 Q3	$3.35M	Hold	7,500	–	–	0.19%	87
2017 Q2	$3.68M	Buy	+7,500	New	+$3.28M	0.23%	81

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eventide Asset Management's REGN Position: Q1 2021 in Review

Eventide Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 30,900 shares — an estimated $14.9M sold.

Eventide Asset Management first reported a position in REGN in Q2 2017 and held it in 10 quarters. The position peaked at $19.3M in Q2 2020. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

Eventide Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Eventide Asset Management sold 30,900 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $14.9M.
Eventide Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 10 quarters.
Eventide Asset Management's Regeneron Pharmaceuticals position peaked at $19.3M in Q2 2020.
924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Eventide Asset Management's 13F filing for Q1 2021, filed 14 May 2021.